Cardiogenic shock complicating acute myocardial infarction: the use of coronary angioplasty and the integration of the new support devices into patient management.

Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation (2009) 2.60

Predictors of outcome after percutaneous treatment for cardiogenic shock. Heart (2005) 0.93

Management of cardiogenic shock complicating acute myocardial infarction: towards evidence based medical practice. Heart (2000) 0.86

Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction. Heart (2004) 0.82

Percutaneous coronary intervention in cardiogenic shock complicating acute ST-elevation myocardial infarction-a single centre experience. Indian Heart J (2012) 0.81

Management and outcome of cardiogenic shock complicating acute myocardial infarction in hospitals with and without on-site catheterisation facilities. Heart (2001) 0.78

A review of cardiogenic shock in acute myocardial infarction. Curr Cardiol Rev (2008) 0.76

Optimal therapy for cardiogenic shock: the emerging role of coronary angioplasty. J Am Coll Cardiol (1992) 0.75

Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 13.93

The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature (1997) 13.09

Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med (1994) 6.78

Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. N Engl J Med (1996) 6.68

Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94

Smoking initiation by adolescent girls, 1944 through 1988. An association with targeted advertising. JAMA (1994) 4.74

Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53

Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation (2000) 4.46

The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export. Curr Biol (1997) 4.35

Diagnostic risk adjustment for Medicaid: the disability payment system. Health Care Financ Rev (1996) 4.34

Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A (1994) 4.21

American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol (2001) 4.20

Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19

Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation (1999) 4.14

Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation (1998) 3.92

Improving health-based payment for Medicaid beneficiaries: CDPS. Health Care Financ Rev (2000) 3.87

Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 3.82

Association between myeloperoxidase levels and risk of coronary artery disease. JAMA (2001) 3.74

Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61

Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation (1990) 3.49

Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38

Outmigration for coronary bypass surgery in an era of public dissemination of clinical outcomes. Circulation (1996) 3.32

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis (1998) 3.09

Changes in population attitudes about where smoking should not be allowed: California versus the rest of the USA. Tob Control (2004) 3.06

A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04

Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol (2001) 2.99

Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med (1996) 2.83

Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA (1997) 2.77

Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients. Circulation (2001) 2.77

Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA (1999) 2.67

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53

Reliability of goniometric measurements. Phys Ther (1978) 2.52

Smoking initiation rates in adults and minors: United States, 1944-1988. Am J Epidemiol (1994) 2.52

Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med (1990) 2.48

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis (1999) 2.48

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet (1994) 2.45

Cardiogenic shock complicating acute coronary syndromes. Lancet (2000) 2.42

Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol (1999) 2.36

Randomized trial of periportal peritoneal bupivacaine for pain relief after laparoscopic cholecystectomy. Br J Surg (1996) 2.33

The American College of Cardiology National Database: progress and challenges. American College of Cardiology Database Committee. J Am Coll Cardiol (1997) 2.31

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J (2001) 2.30

Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem (1998) 2.27

The occurrence of C-H...O hydrogen bonds in proteins. J Mol Biol (1995) 2.27

Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem (1998) 2.24

Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation (1991) 2.23

Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation (1997) 2.23

Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Circulation (1991) 2.18

Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol (1992) 2.18

Intracoronary fibrinolytic therapy in acute myocardial infarction. Report of a prospective randomized trial. N Engl J Med (1983) 2.18

C-reactive protein: a 'golden marker' for inflammation and coronary artery disease. Cleve Clin J Med (2001) 2.17

Analysis of coronary angioplasty practice in the United States with an insurance-claims data base. Circulation (1993) 2.16

Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation (2001) 2.12

Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1995) 2.12

Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. JAMA (1997) 2.11

Cost-efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol (1996) 2.11

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA (2000) 2.11

Myonecrosis after revascularization procedures. J Am Coll Cardiol (1998) 2.11

Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation (1998) 2.09

American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on cardiac catheterization laboratory standards. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2001) 2.09

Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA (1999) 2.08

Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation (1995) 2.08

Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. The Percutaneous Excimer Laser Coronary Angioplasty Registry. Am J Cardiol (1992) 2.08

Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 2.08

Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol (1996) 2.07

Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J (2002) 2.06

Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation (1995) 2.06

Immediate sealing of arterial puncture sites after cardiac catheterization and coronary interventions: initial U.S. feasibility trial using the Duett vascular closure device. Catheter Cardiovasc Interv (2000) 2.04

Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. Stroke (1998) 2.03

One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation (1996) 2.03

The last word on GUSTO, for now. Ann Intern Med (1994) 2.02

Practice guidelines and physician scorecards: grading the graders. Cleve Clin J Med (1997) 2.00

Quality of life for people with dementia living in residential and nursing home care: the impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs. Int Psychogeriatr (2001) 1.96

Isolation of an antigen of Neisseria gonorrhoeae involved in the human immune response to gonococcal infection. J Bacteriol (1969) 1.95

Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet (2004) 1.94

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation (1998) 1.93

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med (1995) 1.93

Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol (1996) 1.91

Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J (1990) 1.90

Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ (2005) 1.89

Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group. Circulation (1991) 1.89

Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87

Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955--1977. Semin Arthritis Rheum (1979) 1.87

Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation (1990) 1.83

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation (2001) 1.83